Home > News > EQUIA Forte Multicenter Study
Back
EQUIA Forte Multicenter Study

Date Released: Jul 15, 2020

GC EQUIA Forte® – Interim Results from Complex Clinical Trial Illustrate Restorative Success*

 

The Glass Hybrid technology represents the next big leap in restorative dentistry. EQUIA Forte® follows the hugely successful EQUIA® restorative system which was launched in 2007*†. A long-term multicenter study was initiated in 2015 to assess the clinical performance of EQUIA Forte compared to a nanohybrid composite resin (Tetric EvoCeram®, Ivoclar Vivadent^) in medium to large Class II restorations*.   

 

Currently, a long-term, split-mouth, randomized multicenter clinical trial is being performed in four countries. The investigation teams are respectively led by Prof. Ivana Miletić (Croatia), Prof. Matteo Basso (Italy), Prof. Dejan Marković (Serbia), and Prof. Lezize Sebnem Turkun (Turkey). The size and complexity of the study brought many challenges; such as cultural and regulatory differences, large number of patients and restorations, monitoring and evaluation process, and compliance with the highest methodological standards. 

 

Achieving a significant sample size is another challenge in split-mouth design studies. Therefore, recruiting a high number of patients while maintaining strict inclusion/exclusion criteria was highly prioritized from the beginning of the trial.

With 180 patients and 360 restorations, the study generated big data. These were not only documented with numeric data but also with impressions, models, scans and pictures. All the data was anonymized and stored in a central database for evaluation and statistical analysis. 

 

Prevailing all complexities, the investigation teams demonstrated not only their expertise by publishing the 2-year results in The Journal of Adhesive Dentistry but also their scientific commitment by continued follow up of the study in its fourth year. 

 

The next goal for the investigators is to create a model to measure the wear of the restorations over the time. 

 

The EQUIA restorative system has over a decade of solid clinical evidence†. The recent clinical performance demonstrated by EQUIA Forte compared to a nanohybrid composite resin further confirms that the EQUIA restorative system is a reliable, long-term restorative for clinicians*.

 

For more study information, please visit: https://jad.quintessenz.de/index.php?doc=abstract&abstractID=44547/

†https://europe.gc.dental/sites/europe.gc.dental/files/products/downloads/equiaforte/reference/REF_Scientific_Sheet_EQUIA_family.pdf

 

 

 

* The study was led by Dr. Ivana Miletić, Professor in the Department of Endodontics and Restorative Dentistry, at Zagreb University, Croatia, working with a team of highly regarded professors from four European dental schools, as cited above. The study is registered in ClinicalTrials.gov (No.: NCT02717520). This research was supported by research grants from the University of Zagreb, Croatia. GC Europe provided materials free of charge. Study available from: Miletić I, Baraba A, Basso M, et al. Clinical Performance of a Glass-Hybrid System Compared with a Resin Composite in the Posterior Region: Results of a 2-year Multicenter Study. J Adhes Dent. 2020;22(3):235-247. doi:10.3290/j.jad.a44547. ^Not trademarks of GC Corporation.

EQUIA Forte is for use only by a dental professional in the recommended indications.

Always read and follow the instructions for use. EQUIA Forte is contraindicated for pulp capping. Avoid use of this product in patients with known allergies to glass ionomer cement, acrylate monomer, methacrylate monomer or methacrylate polymer. In rare cases the product may cause sensitivity in some people. If any such reactions are experienced, discontinue the use of the product and refer to a physician. For more information visit www.gcaustralasia.com or contact your GC Specialist.

 

GC Australia
PO Box 504, Matraville
Sydney NSW 2036
Australia
Tel: +61-2-9301 8200

Follow Us
Stay Connected
Company News